AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 281 min read$INBX

Lappe Mark purchased $999K of INBX (indirect holdings)

Lappe Mark (Chief Executive Officer) purchased 10,000 indirectly-held shares of Inhibrx Biosciences, Inc. (INBX) at an average of $99.88 ($98.87–$101.70, $1.00M total) across 4 trades over 2026-09-25 to 2026-09-28.

Original reporting
SEC EDGAR · Lappe Mark
Published Sep 28, 2026, 9:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 2:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INBX
Bullish
medium confidence
Mentioned
$INBX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INBXBullishLow
01

Why it matters

The filing provides fresh, material information about insider confidence, offering a modest trading edge.

02

Market read

A small insider buy by the CEO may generate slight positive sentiment but is unlikely to cause major price movement.

03

What to watch

The transaction size is modest and may not move the stock significantly; other market forces could dominate price action.

Relevance 6/10Novelty 4/10Timing: filing date Sep 28, 2026

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the CEO's recent purchase.

Company-level read

Ticker impact

$INBXBullishMedium confidence
Context

CEO Mark Lappe purchased 10,000 shares for $998,784, increasing his stake to 740,548 shares.

Expected impact

modest upward pressure as the market prices in the insider buy

Evidence & confidence

A $1M open‑market purchase by the CEO is a positive signal, but the amount is small relative to the company's market cap.

Market effects

Sector

May signal confidence in the biotech sector, but impact is limited to INBX.

Regional

No broader regional effect; confined to U.S. biotech investors.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Company
    Inhibrx Biosciences, Inc.

    Biotech firm listed on NASDAQ under ticker INBX.

  • Person
    Mark Lappe

    Chief Executive Officer of Inhibrx Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INBX insider trading history →

Related articles

SEP 8
$INBXMedAI 8/10

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Inhibrx Biosciences (INBX) reported positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs 26.5% for pembrolizumab alone, with 9.6-month median PFS. HPV+ patients saw even stronger results. The company plans to expand the trial and explore further applications. INBRX-106 is a hexavalent OX40 agonist.

prnewswire.com2 min
SEP 8
$INBXHighAI 8/10

Inhibrx stock jumps on positive cancer drug trial results

Inhibrx Biosciences (NASDAQ:INBX) shares rose 6% after reporting positive Phase 2 trial results for INBRX-106 combined with pembrolizumab in head and neck cancer. The combination showed a 48.3% response rate vs. 26.5% for pembrolizumab alone. The study included 63 patients, with notable improvements in HPV-positive patients. The company plans to expand the trial and align with the FDA for a potential accelerated pathway.

investing.com2 min
AUG 13
$INBXMedAI 8/10

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.

prnewswire.com4 min
AUG 13
$INBXMed

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program

SEC EDGAR 8-K6 min